Courtney Bowers
Family · Glens Falls, NYNPI 1679027684
Payments from drug & device makers
Across 128 payments — averaging $20.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$603
- AbbVie$480
- Lilly USA, LLC$406
- Amgen$173
- GSK$145
- Indivior Inc.$106
- plus $682 from 18 others
What the payments were for
- Food & beverage$2,596100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 31 | $603 |
| AbbVie | 23 | $480 |
| Lilly USA, LLC | 20 | $406 |
| Amgen | 9 | $173 |
| GSK | 7 | $145 |
| Indivior Inc. | 5 | $106 |
| AstraZeneca | 5 | $97 |
| Johnson & Johnson | 5 | $82 |
| Pfizer | 4 | $82 |
| Idorsia Pharmaceuticals US Inc | 3 | $58 |
| Dexcom, Inc. | 2 | $46 |
| Axsome Therapeutics, Inc. | 2 | $39 |
| Exact Sciences | 1 | $33 |
| Biogen | 1 | $30 |
| Astellas Pharma US Inc | 1 | $30 |
| Boehringer Ingelheim | 1 | $26 |
| Boston Scientific | 1 | $23 |
| Abbott | 1 | $22 |
| Merck | 1 | $22 |
| Alkermes, Inc. | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
How this compares
$2,596 in reported general payments places this provider in the 85th percentile of 8,883 family providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProliaDenosumab | 11 | $18,597 |
| EliquisApixaban | 17 | $17,982 |
| MounjaroTirzepatide | 16 | $17,948 |
| OzempicSemaglutide | 11 | $10,363 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,133 |
| Atorvastatin Calcium | 186 | $1,826 |
| Rosuvastatin Calcium | 101 | $1,456 |
| Ezetimibe | 52 | $1,169 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 28 | $986 |
| Duloxetine Hcl | 11 | $779 |
| Levothyroxine Sodium | 77 | $730 |
| Lansoprazole | 14 | $629 |
| Fluticasone Propionate | 29 | $607 |
| Metoprolol Succinate | 54 | $594 |
| Omeprazole | 56 | $543 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenProlia | $173 | $18,59711 claims |
| PfizerEliquis | $82 | $17,98217 claims |
| Lilly USA, LLCMounjaro | $406 | $17,94816 claims |
| Novo NordiskOzempic | $603 | $10,36311 claims |
| GSKTrelegy Ellipta | $145 | $7,13312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,883 family providers in New York.
Other family in Glens Falls
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
- Sheri HillNorth Syracuse$165K
- Cathrine CurtinBronxville$155K
- Mary Sullivan-WhalenNew York$137K
- Sarah AljahmiRockville Centre$87K
- John de OcaStaten Island$86K
- Fara StrickerGlen Oaks$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.